Pharmaceuticals, Biotechnology and Life Sciences
Sanofi announced on Tuesday that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for lixisenatide.
ImmuPharma PLC the specialist drug discovery and development company, has announced the appointment of Tim McCarthy as Non-executive Chairman, with immediate effect.
Veidekke’s Danish subsidiary Hoffmann has been awarded a contract to build a new national research and treatment centre for particle therapy in Aarhus in Jutland.
Meiji Seika Pharma Co., Ltd. announced on Tuesday that the U.S. Food and Drug Administration (FDA) has designated the Company’s lead antibiotic product, ME1100 (arbekacin inhalation solution), as a Qualified Infectious Disease Product (QIDP) for the adjunctive treatment of mechanically ventilated patients with bacterial pneumonia.
Several individuals in German-speaking Switzerland are suspected of offences against the Therapeutic Products Act.
Pfizer Inc., the specialist in making contraceptive medicine, best known for making Viagra, has announced that its injectable contraceptive, Sayana Press (medroxyprogesterone acetate), is now available to women in the United Kingdom (UK) for administration by self-injection.
Teva Pharmaceutical Industries Ltd. announced on Monday that its glatiramer acetate injection was approved by the Japanese Ministry of Health, Labour and Welfare (MHLW)…
New clinical data and abstracts on Roche’s Esbriet (pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF) are being presented at the European Respiratory Society (ERS) congress in Amsterdam.
Bayer CropScience inaugurated its new European Oilseed Processing Center in Monheim at a ceremony attended by industry representatives, authorities, agricultural stakeholders and customers.
Eli Lilly and Company and Incyte Corporation have announced positive top-line results of RA-BEGIN, the third Phase 3 study evaluating the safety and efficacy of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis (RA).